IP Library Granted Patent US 11,385,241
Granted Patent B2
US 11,385,241 · App. 16/334,033 · Granted Jul 12, 2022

Methods of prognosis and treatment

Inventors: Eran Eden (Haifa, IL); Kfir Oved (Hof HaCarmel, IL); Assaf Cohen-Dotan (Natania, IL); Roy Navon (Tel-Aviv, IL); Olga Boico (Haifa, IL); Meital Paz (Haifa, IL)
Assignee: MeMed Diagnostics Ltd.
G01N33/6893G01N33/50G01N33/52G01N33/53G01N33/582G01N33/60G01N33/6863G01N33/6869G16H50/20G16H50/30G16H50/70C07K14/4716C07K14/4737C07K14/522C07K14/525C07K14/5412G01N2333/52G01N2333/525G01N2333/5412G01N2800/26
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,385,241
App. No.
16/334,033
Granted
Jul 12, 2022
Kind
B2
Abstract

A method of determining a management course for treating a subject showing symptoms of a disease is disclosed. The method comprises measuring the TRAIL protein level in a blood sample of the subject, wherein when the TRAIL level is below a predetermined amount, the subject is treated as a high-risk patient.

Claims (11)

1. A method for triaging subjects comprising measuring the TRAIL protein level in a blood sample of a subject showing symptoms of an infectious disease, wherein the subject has a normal troponin level, and wherein when the TRAIL level is below 30 pg/ml, the subject is admitted to a hospital.

2. The method of claim 1 further comprising managing the subject with a management selected from the group consisting of mechanical ventilation, invasive monitoring, last-resort drug, sedation, intensive care admission and surgical intervention.

3. The method of claim 1 , wherein said blood sample is a fraction of whole blood.

4. The method of claim 3 , wherein said fraction is serum or plasma.

5. The method of claim 1 , wherein said blood sample comprises cells selected from the group consisting of lymphocytes, monocytes and granulocytes.

6. The method of claim 1 , wherein said measuring is determined electrophoretically or immunochemically.

7. The method of claim 6 , wherein said immunochemical determination is measured by lateral flow immunoassay, flow cytometry, radioimmunoassay, immunofluorescence or by an enzyme-linked immunosorbent assay.

8. The method of claim 1 , wherein the subject has an infectious disease.

9. The method of claim 1 , wherein the symptoms comprise fever.

10. The method of claim 1 , wherein the triaging further comprises measuring the level of at least one additional determinant selected from the group consisting of IP10, CRP, PCT, and IL-6.

11. The method of claim 1 , wherein when the TRAIL level is below 25 pg/ml, the subject is admitted to a hospital.

Assignments (2)
SECURITY INTEREST Recorded Mar 11, 2026
From: MEMED DIAGNOSTICS LTD.
To: WTI FUND X, INC.; WTI FUND XI, INC.
Reel/Frame 074048/0278 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 27, 2019
From: EDEN, ERAN; OVED, KFIR; COHEN-DOTAN, ASSAF; NAVON, ROY; BOICO, OLGA; PAZ, MEITAL
To: MEMED DIAGNOSTICS LTD.
Reel/Frame 048708/0953 →
Continuity (2)
Provisional Application 62401296 · Sep 29, 2016
Related Publication 20190271709A1 · Sep 5, 2019
Cited By (3)
US 12,188,934 US 12,338,497 US 12,392,775